Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 Cell in Relapsing/Refractory Autoimmune Diseases
NCT07104721Phase 1Recruiting
- Sponsor
- China Immunotech
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YTS-109 in systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis (SSc) and 4 more, sponsored by China Immunotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 52 weeks. Started Aug 2025; status: recruiting.
02
Drugs
YTS-109
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)systemic sclerosis (SSc)inflammatory myopathy (IIM)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07104721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104721.